Core Viewpoint - Axsome Therapeutics has experienced a decline in share price of approximately 6.6% since its last earnings report, underperforming the S&P 500, raising questions about the potential for continued negative trends or a breakout ahead of the next earnings release [1][2]. Financial Performance - In Q4 2025, Axsome reported a loss of 71 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 70 cents, compared to a loss of 96 cents per share in the same quarter the previous year [3]. - Total revenues surged by 65% year over year to $196 million in Q4, exceeding the Zacks Consensus Estimate of $193 million, primarily driven by strong sales of Auvelity and other marketed drugs [4]. - Net product revenues reached $194.7 million in Q4, reflecting a 66% year-over-year increase, with royalty revenues totaling $1.3 million [5]. Product Sales Breakdown - Auvelity sales amounted to $155.1 million, up 68% from the previous year, surpassing the Zacks Consensus Estimate of $151 million, with approximately 225,000 prescriptions recorded, marking an 8% sequential increase and a 42% year-over-year increase [6]. - Sunosi generated net product sales of $36.7 million in Q4, a 40% increase from the previous year, with total prescriptions growing 11% year over year to 54,000 [7]. - Symbravo recorded sales of $4.1 million in Q4, an increase from $2.1 million in Q3 2025 [7]. Expense Overview - Research and development expenses were $48.8 million, down 11.3% from the previous year, attributed to the completion of label expansion studies [8]. - Selling, general, and administrative expenses totaled $169.3 million, up 49.4% year over year, driven by increased commercial activities for Auvelity and ongoing launch activities for Symbravo [9]. Cash Position - As of December 31, 2025, Axsome had cash and cash equivalents of $322.9 million, slightly down from $325.3 million as of September 30, 2025 [9]. Market Sentiment - Estimates for Axsome have trended downward over the past month, with a consensus estimate shift of -49.28% [10]. - The company currently holds a strong Growth Score of A but lags in Momentum and Value Scores, receiving an overall VGM Score of C [12]. - The downward trend in estimates has led to a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [13].

Core Insights - Axsome Therapeutics (AXSM) is experiencing significant growth driven by its lead drug, Auvelity (AXS-05), which is approved for major depressive disorder and has contributed substantially to the company's revenue since its U.S. launch in 2022 [1][9]. Sales Performance - In 2025, Auvelity achieved sales of $507.1 million in the U.S., reflecting a year-over-year increase of approximately 74% [2][9]. - The sales growth is attributed to an increase in unit sales volume, with expectations for continued momentum into 2026 [2]. - Sunosi, another drug in Axsome's portfolio, generated $124.8 million in sales in 2025, marking a 32% increase year-over-year [5][9]. - Axsome's newest product, Symbravo, launched in June 2025, recorded $6.6 million in sales in its first year [5]. Regulatory Developments - The FDA has accepted Axsome's supplemental new drug application (sNDA) for AXS-05 to treat Alzheimer's disease agitation, with a priority review and a decision expected by April 30, 2026 [3]. Clinical Development - Axsome plans to initiate a pivotal phase II/III study of AXS-05 for smoking cessation in the second quarter of 2026 [4]. Competitive Landscape - The CNS market remains competitive, with Acadia Pharmaceuticals' Nuplazid generating $691.9 million in sales in 2025, up 14.7% year-over-year [7]. - Sunosi may face competition from Jazz Pharmaceuticals' sleep disorder drugs, while Symbravo is expected to compete with established migraine treatments from Pfizer and AbbVie [8]. Valuation and Market Performance - Year-to-date, Axsome's shares have declined by 15.6%, contrasting with a 5.7% increase in the industry [10]. - Axsome's price-to-sales (P/S) ratio stands at 12.22, significantly higher than the industry average of 2.45, although below its five-year mean of 14.41 [11]. Earnings Estimates - The Zacks Consensus Estimate for 2026 has shifted from earnings of $0.34 per share to a projected loss of $1.29 per share, with 2027 estimates also decreasing from $5.85 to $5.12 [12].

Axsome Therapeutics Conference Call Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Date**: March 09, 2026 - **Key Speakers**: Mark Jacobson (COO), Nick Pizzie (CFO) Key Points Auvelity Performance and Strategy - Auvelity annualized revenue at the end of 2025 was just over **$600 million**, marking its third full year since launch in 2022, outperforming peers in the market [6][7] - The sales force expanded from **160** to **300** representatives in 2025, with plans to double to **600** in 2026, focusing on Major Depressive Disorder (MDD) and the anticipated approval for Agitation in Alzheimer’s Disease (ADA) [7][8] - Peak sales projections for Auvelity are estimated between **$1 billion** to **$3 billion** for MDD and **$1.5 billion** to **$3 billion** for ADA [7] - Market access has improved to **86%** coverage of total lives, with **100%** coverage in the government channel and **78%** on the commercial side [21][22] - Direct-to-consumer (DTC) advertising began in September 2025, with adjustments made based on learnings from the initial campaign [18][19] Clinical and Market Dynamics - Auvelity's clinical profile shows a distinct safety and tolerability profile, with over **50%** of prescriptions now coming from first and second-line treatments [8][9] - The product is gaining traction in primary care, with about **33%** of scripts originating from this sector [9] - The company is reallocating resources from DTC to expand the sales team, anticipating that this will enhance the effectiveness of future DTC campaigns [18][19] Upcoming Indications and Trials - The PDUFA date for ADA is set for **April 30, 2026**, with preparations underway for potential FDA approval [23][24] - Axsome is also exploring a smoking cessation indication for Auvelity, with clinical operations set to begin soon [30][32] Symbravo Launch - Symbravo is performing well in the migraine space, with a focus on later-line treatment due to payer management [36][37] - The sales force for Symbravo is currently **100 reps**, with a strategy to refine the launch based on early utilization data [40][41] - Market access for Symbravo is around **50%** covered lives, with recent contracts signed to improve access [45] Sunosi Growth - Sunosi has seen a **40%** year-over-year growth, supported by a dedicated team of **70 reps** [55][57] - The company is optimistic about further accelerating revenue through four indications currently in development [57] AXS-14 and AXS-17 Developments - AXS-14 (esreboxetine) is targeting the fibromyalgia market, with a new phase 3 trial launched after a previous Refuse to File due to trial design issues [87][89] - AXS-17 is a new product for epilepsy, with plans for phase 2 enabling work in 2026, focusing on unmet needs in the epilepsy space [106][107] AXS-12 Submission - AXS-12, targeting narcolepsy with a focus on cataplexy, is at the NDA stage, with submission expected soon [121] Additional Insights - The company is strategically focusing on expanding its pipeline and market presence while addressing regulatory feedback to enhance product approvals [89][90] - There is a strong emphasis on understanding market dynamics and patient needs to drive product utilization and acceptance [41][57]

Core Thesis - Axsome Therapeutics, Inc. is positioned as a differentiated neuro-focused biotech with multiple commercial assets and a late-stage pipeline targeting large, underserved markets [3][6] - The stock was trading at $163.19 with a forward P/E of 370.37, indicating high investor expectations [1][3] Commercial Products - Axsome has three products on the market, with Auvelity for major depressive disorder being the primary growth driver, showing a 69% sales increase in Q3 and projected peak sales of approximately $2 billion [4][6] - Sunosi, indicated for sleep apnea, experienced a 35% growth last quarter, while Symbravo for acute migraines is expected to reach a peak opportunity of $400 million [4][6] Pipeline Potential - The pipeline includes AXS-12 for narcolepsy, projected as a potential $500 million product, and AXS-05 for Alzheimer's agitation, which could exceed $1.5 billion in peak sales with possible approval in the first half of 2026 [5] - Another Phase III candidate targeting ADHD may represent an additional $1 billion opportunity [5] Financial Performance - Overall sales have risen 63% and 72% in the past two quarters, with analysts forecasting over 50% growth next year [6] - Breakeven is expected in 2026 as the company scales, indicating a positive trajectory towards profitability [6] Market Sentiment - The stock has recently broken to new highs after a nine-month consolidation period, suggesting improving market sentiment [6] - The combination of accelerating revenues and multiple regulatory catalysts presents a compelling growth narrative with significant upside potential [6][8]

Core Thesis - Axsome Therapeutics, Inc. is positioned as a differentiated neuro-focused biotech with multiple commercial assets and a late-stage pipeline targeting large, underserved markets [3][6] - The stock was trading at $163.19 with a forward P/E of 370.37, indicating high investor expectations [1][3] Commercial Products - Axsome's lead product, Auvelity for major depressive disorder, saw sales increase by 69% in the third quarter, with projected peak sales of approximately $2 billion [4] - Sunosi, indicated for sleep apnea, experienced a 35% growth last quarter, while Symbravo for acute migraines is expected to reach a peak opportunity of $400 million [4] - Overall sales have risen by 63% and 72% in the past two quarters, with analysts forecasting over 50% growth next year [6] Pipeline Potential - The pipeline includes AXS-12 for narcolepsy, projected as a potential $500 million product, and AXS-05 for Alzheimer's agitation, which could exceed $1.5 billion in peak sales [5] - Another Phase III candidate targeting ADHD and related indications may represent an additional $1 billion opportunity [5] Financial Outlook - Breakeven is expected in 2026 as scale improves, indicating a path toward profitability [6] - The stock has recently broken to new highs after a nine-month consolidation, suggesting improving market sentiment [6]

Core Insights - Axsome Therapeutics reported a loss of 71 cents per share in Q4 2025, which was wider than the expected loss of 70 cents, compared to a loss of 96 cents per share in the same quarter last year [1][6] - The company's total revenues increased by 65% year over year to $196 million in Q4, surpassing the consensus estimate of $193 million, primarily driven by strong sales of Auvelity [2][6] Financial Performance - Total revenues in Q4 included product revenues from Auvelity, Sunosi, and Symbravo, with net product revenues reaching $194.7 million, a 66% increase year over year [3] - Auvelity sales were $155.1 million, up 68% from the previous year, exceeding the consensus estimate of $151 million [4][6] - Sunosi's net product sales were $36.7 million, reflecting a 40% increase year over year, with total prescriptions growing 11% to 54,000 [7] Expenses and Cash Position - Research and development expenses were $48.8 million, down 11.3% from the previous year due to the completion of label expansion studies [10] - Selling, general, and administrative expenses rose to $169.3 million, a 49.4% increase year over year, attributed to higher commercial activities for Auvelity and ongoing launch activities for Symbravo [11] - As of December 31, 2025, Axsome had cash and cash equivalents of $322.9 million, slightly down from $325.3 million at the end of Q3 2025, which is expected to fund operations into cash flow positivity [12] Full-Year Results - For the full year 2025, Axsome generated revenues of $638.5 million, a 66% growth year over year, with an adjusted loss of $3.68 per share, an improvement from a loss of $5.99 in the previous year [13] Pipeline Developments - Axsome is conducting label expansion studies for Auvelity and has submitted a supplemental new drug application for AXS-05 for Alzheimer's disease agitation, with a decision expected by April 30, 2026 [14] - The company plans to initiate a pivotal phase II/III study of AXS-05 for smoking cessation in Q2 2026, and is evaluating AXS-12 and AXS-14 for multiple CNS indications [15][16] - AXS-12 is in late-stage studies for narcolepsy, with a potential NDA submission planned for the first quarter of 2026 [16] - Axsome is also conducting phase III studies for solriamfetol targeting ADHD, MDD, binge eating disorder, and excessive sleepiness associated with shift work disorder, with data expected in 2026 and 2027 [17][18]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [6][12] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% compared to the prior year, and total sales for Auvelity reached $507.1 million, representing a 74% year-over-year increase [12][13] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [16] - Net loss for the full year was $183.2 million, or $3.68 per share, compared to a net loss of $287.2 million, or $5.99 per share for 2024 [17] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth in prescriptions [6][19] - Sunosi generated net product revenue of $36.7 million for Q4, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [13] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [13] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [19] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [20] - Symbravo's overall payer coverage is approximately 52% at the start of the year [22] Company Strategy and Development Direction - The company is advancing a broad CNS pipeline with 5 novel product candidates across 9 high-impact indications [6] - Plans to conduct two Phase 3 trials in ADHD, one in children and one in adolescents, are on track for initiation in the first half of the year [9] - The company aims to expand its sales force to approximately 600 representatives to support growth in MDD and potential launch in Alzheimer's disease agitation [21][59] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver new treatment options for patients living with CNS disorders, supported by a scalable commercial platform [6][11] - The company anticipates that its current cash balance is sufficient to fund operations into cash flow positivity based on the current operating plan [17] - Management is optimistic about the potential impact of the upcoming launch for Alzheimer's disease agitation, with preparations underway [69] Other Important Information - The company has made significant progress with its NDA package for AXS-12 in narcolepsy and expects to submit that imminently [8] - The acquisition of AZD7325, a novel oral GABA A alpha-2/3 receptor positive allosteric modulator, is planned for evaluation in epilepsy [10] Q&A Session Summary Question: Implications of the new FDA publication on the one trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA [28] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the focus is currently on preparing for Phase II readiness [33] Question: Coverage evolution for Auvelity post-ADA label approval - Existing coverage should generally apply to the new indication, but there may be additional efforts needed for Medicare coverage [36] Question: Growth drivers for Sunosi - Growth is driven by both volume and improved access across OSA and narcolepsy markets [44] Question: Sales force expansion rationale - The expansion aims to accelerate growth in MDD and prepare for potential Alzheimer's agitation indication [59] Question: Coverage evolution for Symbravo - The secured contract with a third large GPO allows for active negotiation with payers, with optimism for increased coverage [63]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [6][12] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% year-over-year, and total sales for Auvelity reached $507.1 million, representing a 74% year-over-year increase [12][13] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [17] - Cash and cash equivalents at year-end were $323 million, compared to $315 million at the end of 2024 [18] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth in prescriptions [5][20] - Sunosi posted Q4 net product revenue of $36.7 million, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [13][25] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [14] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [20] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [21] - Symbravo's payer coverage is approximately 52% at the start of the year, with ongoing negotiations expected to expand this coverage [24] Company Strategy and Development Direction - The company is focused on scaling growth across its commercial organization and expanding adoption of CNS medicines [25] - A significant expansion of the Auvelity sales force to approximately 600 representatives is planned to support growth in MDD and potential Alzheimer's disease agitation [22][64] - The company is advancing a broad CNS pipeline, including five novel product candidates across nine high-impact indications [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential impact of Auvelity in addressing Alzheimer's disease agitation, with launch readiness activities underway [7][74] - The company anticipates continued momentum in its commercial business and expects to achieve cash flow positivity based on its current operating plan [18] - Management highlighted the importance of ongoing negotiations with payers to ensure access for both MDD and ADA indications [56] Other Important Information - The company has made significant progress in its CNS pipeline, including planned trials for AXS-05 in smoking cessation and AXS-12 in narcolepsy [8][9] - The company acquired AZD7325, a novel oral GABA A receptor modulator, to evaluate for the treatment of epilepsy [10] Q&A Session Summary Question: Implications of the new FDA publication on trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA [29][30] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the focus is currently on preparing for phase II readiness [35][36] Question: Coverage evolution for Auvelity post-ADA label approval - Existing coverage should generally apply to the new indication, but additional efforts are being made for Medicare coverage [40][41] Question: Drivers of Sunosi's growth - Growth is driven by both OSA and narcolepsy markets, with positive trends in new patient starts and prescriber behavior [48] Question: Progress of the DTC campaign for Auvelity - The national TV campaign has generated an inflection in new patient starts, with growth seen in primary care and psychiatry [52][53] Question: Expected reimbursement and market access for Auvelity - The goal is to secure access for as many patients as possible, with steady progress in increasing covered lives [56] Question: Coverage evolution for Symbravo - Secured contracts with large GPOs will facilitate negotiations with payers, with optimism about increasing coverage [68][70] Question: Launch readiness for Alzheimer's disease agitation - The company will be ready to launch within a quarter post-approval, with plans to share metrics on script percentages from the ADA space [74]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [4][11] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% compared to the prior year, and total sales for Auvelity reached $507.1 million for the full year, representing a 74% year-over-year increase [12][15] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [15] - Net loss for the full year of 2025 was $183.2 million, or $3.68 per share, compared to a net loss of $287.2 million, or $5.99 per share for 2024 [16] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth contributing to overall revenue [4] - Sunosi generated net product revenue of $36.7 million for Q4, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [12] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [12] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [18] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [19] - Symbravo's overall payer coverage is approximately 52% at the start of the year, with 49% in commercial and 57% in government channels [21] Company Strategy and Development Direction - The company is advancing a broad CNS pipeline with 5 novel product candidates across 9 high-impact indications, including a planned phase 2/3 trial of AXS-05 in smoking cessation [5][6] - AXS-12's NDA submission for narcolepsy is expected imminently, with significant progress made following positive FDA pre-NDA meeting minutes [6] - The company plans to expand its sales force to approximately 600 representatives to support growth in MDD and potential Alzheimer's disease agitation [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver upon vast opportunities for the growing portfolio of CNS medicines, supported by a scalable commercial platform [4][18] - The company anticipates continued momentum in its commercial business and expects to generate significant value through disciplined investment and performance across its CNS portfolios [104] Other Important Information - The company ended the year with $323 million in cash and cash equivalents, compared to $315 million at the end of 2024, indicating sufficient funds to support operations into cash flow positivity [17] - Gross and net discounts for Auvelity and Sunosi are expected to increase due to typical Q1 dynamics, with Symbravo's gross net discount remaining elevated during the launch phase [13] Q&A Session Summary Question: Implications of the new FDA publication on the one trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA, indicating potential for supportive evidence in ongoing studies [26][27] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the company is closely assessing different types of epilepsy for potential clinical success [31][33] Question: Auvelity payer coverage evolution post-ADA label addition - Existing coverage is expected to apply to the new indication, with efforts ongoing to ensure sufficient coverage and utilization management [35][36] Question: Initial launch cadence for Alzheimer's agitation - The company is preparing for a launch within a quarter post-approval, with metrics to be shared regarding script percentages from the ADA space [39][69] Question: Growth drivers for Sunosi - Growth is driven by both volume and improved access, with steady performance in both OSA and narcolepsy markets [44] Question: DTC campaign progress for Auvelity - The national TV campaign launched in late 2025 has generated positive impacts on new patient starts, with ongoing optimization of media spend [46][48] Question: Coverage expectations for Auvelity at steady state - The goal is to secure access for as many patients as possible, with steady progress in increasing covered lives anticipated [50][52] Question: AXS-12 opportunity in narcolepsy - AXS-12 offers compelling treatment options for patients, with strong data in cataplexy and potential benefits in excessive daytime sleepiness [72][74]

Core Insights - Axsome Therapeutics is gaining prominence in the biotech sector, outperforming broader equities over the past five years and showing potential for continued strong performance over the next decade [1][2] Company Overview - Axsome Therapeutics specializes in developing medicines for central nervous system conditions, with approved products like Auvelity for depression and Symbravo for migraines [4] - The company is also advancing AXS-12 for narcolepsy, which has completed phase 3 clinical trials, with regulatory submissions expected in Q4 [6] Market Opportunity - The market for Alzheimer's disease (AD) agitation, which affects over 5 million patients in the U.S., presents a significant commercial opportunity, especially as the aging population increases [5] - Auvelity is positioned to enter a growing market with high unmet needs and limited competition [5] Financial Potential - Axsome's late-stage pipeline has a peak sales potential exceeding $16 billion, while the current market cap stands at $9.3 billion [8] - The company enjoys a gross margin of 90.31% and has patent protection for its products until the 2040s, mitigating risks associated with patent cliffs [8]